APLT

Applied Therapeutics, Inc. [APLT] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

APLT Stock Summary

Top 10 Correlated ETFs

APLT


Top 10 Correlated Stocks

APLT


In the News

03:36 10 Dec 2023 APLT

3 Penny Stocks To Buy According To Insiders In December

Penny stocks – the cheap stocks trading under $5 per share, offer investors massive upside potential alongside higher risk. Since even incremental price moves translate into huge percentage gains in the stock market, timing entries right can set you up for explosive profits.

07:00 10 Dec 2023 APLT

Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting

The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the efficacy of AT-001 (caficrestat) on cardiac functional capacity in patients with diabetic cardiomyopathy (DbCM) Baseline data from ARISE-HF shows patients with DbCM exhibit reduced cardiac functional capacity resulting in decreased physical activity NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it will participate in a Symposium presentation, entitled Diabetic Cardiomyopathy (DbCM): a severe complication of diabetes, at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting to take place October 2-6, 2023 in Hamburg, Germany and online.

04:28 10 Dec 2023 APLT

Applied Therapeutics: Buy For Upcoming Pre-NDA Meeting (I Expect A Positive Outcome)

Applied Therapeutics is a micro-cap with low cash balance, but has major upcoming catalysts (pre-NDA meeting for galactosemia and phase 3 results in diabetic cardiomyopathy) and a huge upside potential. Despite missing the primary endpoint in galactosemia ph3 trial, APLT still plans for NDA submission. The pre-NDA meeting with the FDA this summer will be a big catalyst if positive. I expect a positive outcome from the meeting considering consistent and meaningful clinical benefit in multiple endpoints, orphan and fast-track designation, no alternative treatments, and the significant burden for affected patients.

07:00 10 Dec 2023 APLT

Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association

NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced multiple presentations on AT-001 (caficrestat) and the ARISE-HF Phase 3 study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association to take place June 23 - 26 in San Diego, California.

02:24 10 Dec 2023 APLT

7 Hot Growth Stocks Poised to Triple in 2023

Any investor seeking growth stocks that are poised to triple in 2023 will need a strong appetite for risk. That much is very clear.

11:12 10 Dec 2023 APLT

4 Top Penny Stocks To Buy According To Analysts, Targets Up To 695%

Analysts say these could be penny stocks to buy. Do you agree with their outlook?

11:28 10 Dec 2023 APLT

3 Penny Stocks To Buy According To Analysts, Targets Up To 1,029%

Analysts say these are penny stocks to buy but do you agree? The post 3 Penny Stocks To Buy According To Analysts, Targets Up To 1,029% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

07:00 10 Dec 2023 APLT

Applied Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate in a Neuromuscular & Bone Panel at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 2:10 p.m. ET in Boston.

07:00 10 Dec 2023 APLT

Applied Therapeutics to Present at the SVB Securities Global Biopharma Conference

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present virtually at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023 at 2:20 p.m. ET.

09:14 10 Dec 2023 APLT

7 Top Penny Stocks To Watch With Big News This Week

Hot penny stocks to watch with news this week. The post 7 Top Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

APLT Financial details

Company Rating
Buy
Market Cap
240.18M
Income
-87.18M
Revenue
10.66M
Book val./share
-0.12
Cash/share
0.41
Dividend
-
Dividend %
-
Employees
22
Optionable
No
Shortable
Yes
Earnings
09 Nov 2023
P/E
-3.23
Forward P/E
-3.05
PEG
0.45
P/S
22.53
P/B
-25.53
P/C
7.59
P/FCF
-4.44
Quick Ratio
0.68
Current Ratio
0.8
Debt / Equity
-0.12
LT Debt / Equity
-0
-
-
EPS (TTM)
-1.16
EPS next Y
-1.02
EPS next Q
-0.26
EPS this Y
-47.19%
EPS next Y
-12.22%
EPS next 5Y
-24.39%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
27.03%
-
-
-
-
SMA20
4.37%
SMA50
-6.27%
SMA100
70.71%
Inst Own
43.47%
Inst Trans
0.78%
ROA
-193%
ROE
2266%
ROC
6.06%
Gross Margin
100%
Oper. Margin
-586%
Profit Margin
-818%
Payout
-
Shs Outstand
77.23M
Shs Float
52.28M
-
-
-
-
Target Price
-
52W Range
0.7-3.365
52W High
-
52W Low
-
RSI
72.45
Rel Volume
3.66
Avg Volume
1.04M
Volume
3.81M
Perf Week
53.96%
Perf Month
9.89%
Perf Quarter
111.56%
Perf Half Y
114.48%
-
-
-
-
Beta
1.427
-
-
Volatility
0.3%, 0.28%
Prev Close
16.48%
Price
3.11
Change
24.9%

APLT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-1.8-3.54-4.23-4.09-2.16
Operating cash flow per share
-1.22-2.83-3.56-3.54-2.06
Free cash flow per share
-1.22-2.83-3.56-3.54-2.06
Cash per share
2.053.034.413.160.81
Book value per share
1.732.543.732.440.11
Tangible book value per share
1.732.543.732.440.11
Share holders equity per share
1.732.543.732.440.11
Interest debt per share
00.170.10.070.01
Market cap
86.13M350.04M483.48M229.1M28.75M
Enterprise value
67.39M333.22M427.75M176.55M12.98M
P/E ratio
-5.21-7.71-5.2-2.19-0.35
Price to sales ratio
00000
POCF ratio
-7.7-9.64-6.18-2.53-0.37
PFCF ratio
-7.7-9.64-6.18-2.53-0.37
P/B Ratio
5.4510.735.93.667.08
PTB ratio
5.4510.735.93.667.08
EV to sales
00000
Enterprise value over EBITDA
-5.07-7.31-4.53-1.67-0.16
EV to operating cash flow
-6.03-9.18-5.47-1.95-0.17
EV to free cash flow
-6.03-9.18-5.47-1.95-0.17
Earnings yield
-0.19-0.13-0.19-0.46-2.84
Free cash flow yield
-0.13-0.1-0.16-0.4-2.72
Debt to equity
00.060.020.020.22
Debt to assets
00.040.020.010.02
Net debt to EBITDA
1.410.370.590.50.19
Current ratio
4.573.274.833.341.12
Interest coverage
0-490.13-168.99-190.3187.67
Income quality
0.680.80.830.860.95
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
8.3714.2218.8514.992.28
ROIC
-1.11-1.24-1.09-1.6-14.06
Return on tangible assets
-0.82-0.94-0.89-1.16-2.13
Graham Net
1.561.83.392.09-0.1
Working capital
15.82M32.06M81.36M61.93M3.88M
Tangible asset value
15.82M32.61M81.94M62.54M4.06M
Net current asset value
15.82M30.37M80.03M61.04M3.01M
Invested capital
00.060.020.020.22
Average receivables
00252.5K515K400K
Average payables
1.86M5.9M4.72M5.05M7M
Average inventory
00-252.5K-515K-400K
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-1.04-1.39-1.14-1.67-20.12
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
000.1900
Net income per share
-0.39-0.15-0.17-0.37-0.47
Operating cash flow per share
-0.4-0.42-0.12-0.21-0.16
Free cash flow per share
-0.4-0.42-0.12-0.21-0.16
Cash per share
0.990.810.410.450.41
Book value per share
0.20.11-0.07-0.05-0.12
Tangible book value per share
0.20.11-0.07-0.05-0.12
Share holders equity per share
0.20.11-0.07-0.05-0.12
Interest debt per share
0.050.0500.020.01
Market cap
44.64M28.75M45.71M101.17M225.77M
Enterprise value
6.82M14.07M23.57M67.45M189.62M
P/E ratio
-0.59-1.24-1.21-0.86-1.33
Price to sales ratio
004.2900
POCF ratio
-2.3-1.81-6.54-6.15-15.33
PFCF ratio
-2.3-1.81-6.54-6.15-15.33
P/B Ratio
4.647.08-11.23-23.34-20.44
PTB ratio
4.647.08-11.23-23.34-20.44
EV to sales
002.2100
Enterprise value over EBITDA
-0.35-0.61-2.08-15.85-12.24
EV to operating cash flow
-0.35-0.89-3.37-4.1-12.88
EV to free cash flow
-0.35-0.89-3.37-4.1-12.88
Earnings yield
-0.42-0.2-0.21-0.29-0.19
Free cash flow yield
-0.43-0.55-0.15-0.16-0.07
Debt to equity
0.270.49-0.19-0.44-0.12
Debt to assets
0.050.050.030.040.03
Net debt to EBITDA
1.960.641.957.922.33
Current ratio
1.191.120.870.910.8
Interest coverage
75.91101.4515.0600
Income quality
1.021.10.690.560.35
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
000.5200
Research and developement to revenue
001.4900
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
000.1900
Graham number
1.330.610.520.681.13
ROIC
-1.44-1.1413.681.68
Return on tangible assets
-0.33-0.15-0.31-0.68-0.94
Graham Net
0.01-0.02-0.2-0.11-0.18
Working capital
9M3.88M-4.19M-4.37M-11.02M
Tangible asset value
9.63M4.06M-4.07M-4.33M-11.04M
Net current asset value
8.46M3.01M-5.01M-5.16M-11.75M
Invested capital
0.270.49-0.19-0.44-0.12
Average receivables
282K275.5K280K285K285K
Average payables
7.83M5.75M5.04M5.12M5.35M
Average inventory
-138K2.52M2.52M3.05M5.67M
Days sales outstanding
002.4100
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0037.400
Payables turnover
00000
Inventory turnover
00000
ROE
-1.95-1.432.316.823.84
Capex per share
00000

APLT Frequently Asked Questions

What is Applied Therapeutics, Inc. stock symbol ?

Applied Therapeutics, Inc. is a US stock , located in New york of Ny and trading under the symbol APLT

What is Applied Therapeutics, Inc. stock quote today ?

Applied Therapeutics, Inc. stock price is $3.11 today.

Is Applied Therapeutics, Inc. stock public?

Yes, Applied Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap